Moderate to Severe Chronic Plaque-type Psoriasis
3 clinical trials · Condition
◉ Watch Moderate to Severe Chronic Plaque-type Psoriasis
| Record | Firm | Date |
|---|---|---|
| Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis (NCT03668613) | Novartis Pharmaceuticals | 2018-08-29 |
| Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis (NCT03504852) | Novartis Pharmaceuticals | 2018-06-25 |
| 4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis (NCT01640951) | Novartis Pharmaceuticals | 2012-09-16 |
Track Moderate to Severe Chronic Plaque-type Psoriasis automatically
Every clearance here is in the API, with alerts when new ones post.